Today we are discussing the management of patients with chronic lymphocytic leukemia (CLL), including incorporating the newest approved therapies for CLL: duvelisib and venetoclax.
We are joined by Dr. Ian Flinn, a hematologist/oncologist and the director of the Blood Cancer Research Program at Sarah Cannon Research Institute in Tennessee. Dr. Flinn treats patients with CLL and has taken part in many clinical trials of agents in development for the disease.
Transcript...